ZED1277, a TG2 inhibitor, can be utilized in CD therapy by inhibiting the degradation of peroxisome proliferator-activated receptor γ and decreasing transcellular permeability, in addition to decreasing T cell immune response in CD patients [46,48,49]. This evidence concerns the gene TGM2 and Cowden disease.